IP Library › Granted Patent US 11,261,426
Granted Patent B2
US 11,261,426 · App. 15/189,215 · Granted Mar 1, 2022

Pluripotent stem cell that can be isolated from body tissue

Inventors: Mari Dezawa (Miyagi, JP); Yoshinori Fujiyoshi (Kyoto, JP); Youichi Nabeshima (Kyoto, JP)
C12N5/0607A61K35/28C12N5/0605C12N5/0663C12N5/0665C12N5/0667A61K35/12A61K35/50A61K35/51A61K2035/124C12N5/0662C12N2500/02C12N2500/84C12N2500/90C12N2501/06C12N2501/734C12N2501/998C12N2502/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,426
App. No.
15/189,215
Granted
Mar 1, 2022
Kind
B2
Abstract

Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.

Claims (19)

1. A method for preparing a cell fraction comprising 50% or more of multilineage-differentiating stress enduring cells (MUSE cells), comprising:

exposing mesenchymal cells derived from bone marrow, adipose tissue, skin, umbilical cord or blood to cellular stress conditions selected from the group consisting of low-oxygen culture conditions, serum starvation culture conditions, and sugar starvation culture conditions;

collecting survival cells;

separating the collected cells using SSEA-3 antigen marker as an index; and

recovering a cell fraction comprising 50% or more of MUSE cells,

wherein the MUSE cells in the recovered fraction are characterized by:

(i) SSEA-3(+) and CD105(+);

(ii) no telomerase activity or low telomerase activity as low as that of human fibroblasts;

(iii) the ability to differentiate into the three germ layers;

(iv) exhibit a lack of tumorigenesis;

(v) self-renewal capability; and

(vi) CD117(−) and CD146(−).

2. The method of claim 1 wherein the cellular stress is low-oxygen culture conditions.

3. The method of claim 2 wherein the low-oxygen culture conditions comprise 1% oxygen.

4. The method of claim 3 wherein the mesenchymal cells exposed to stress conditions are derived from bone marrow.

5. The method of claim 3 wherein the mesenchymal cells exposed to stress conditions are derived from adipose tissue.

6. The method of claim 3 wherein the recovered cell fraction comprises 70% or more of MUSE cells.

7. The method of claim 3 wherein the recovered cell fraction comprises 90% or more of MUSE cells.

8. The method of claim 3 wherein the recovered cell fraction comprises 95% or more of MUSE cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2025
From: DEZAWA, MARI; FUJIYOSHI, YOSHINORI; NABESHIMA, YOUICHI
To: MUSECELL INNOVATIONS PTE. LTD.
Reel/Frame 070001/0298 →
Priority Claims (2)
JP JP2011-076635 · Mar 30, 2011 · national
JP JP2011-076643 · Mar 30, 2011 · national
Continuity (5)
Continuation 13435703 · Mar 30, 2012
Continuation In Part 12836264 · Jul 14, 2010
Provisional Application 61213788 · Jul 15, 2009
Provisional Application 61290159 · Dec 24, 2009
Related Publication 20160369232A1 · Dec 22, 2016